Facts and Figures 2014 December 2014

Updated on 12/30/2014 2014 – Facts and Figures 1

France Biotech – 3-5, Impasse Reille – 75014 Paris – Tel : 01 56 58 10 70 – Fax : 01 56 58 20 33

December 2014

Facts and Figures

« We are the present and the future of the Life Sciences Industry, about to succeed in our task: put to the market products willing to meet the patients demand. What a journey and still a lot of achievements to come! »

Pierre-Olivier GOINEAU, President of France Biotech



Table of Contents

France Biotech in a few words ............................................................................... 3

General Information................................................................................................ 4

Company Creations and Liquidations.................................................................... 5

Company Size ........................................................................................................ 6

Revenues ................................................................................................................ 7

Total R&D Expenses .............................................................................................. 8

List of the 10 most reimbursed drugs in 2013 ....................................................... 9

Top 15 selling drugs 2013 vs. 2020 ..................................................................... 10

Top 10 worldwide fundraisings in 2013 ............................................................... 11

Publicly-listed biotechnology companies ............................................................. 12

Market Capitalization of the 54 French Life Sciences companies on December

29th, 2014* ............................................................................................................ 23

Distribution of French Life Sciences companies by Industry Sector .................. 24

Fundraising by French Biotech companies ......................................................... 25

Mergers and Acquisitions in France and Europe ................................................ 38

Recent Operations* .............................................................................................. 39

Main venture capital actors in the French Life Sciences Industry ...................... 48

Financial support from Bpifrance and the ANR ................................................... 49

Competitiveness Clusters .................................................................................... 51



France Biotech in a few words Founded in September 1997

156 members among which 20 new in 2014

7 work groups:

o Corporate Finance

o Social and legal o Diagnostics o Business development

o Development of new therapeutic products o Innovative Medical devices & Diagnostics o Jurists

o Industrial production

Annual studies:

o Panorama of the French Life Sciences Industry® o The French Life Sciences Industry Association Directory

o Salary survey of the French Life Sciences Industry

17 entrepreneurs on the Board of France Biotech!

France Biotech is the association of French companies in the Life Sciences sector and their partners. Its mission is to contribute to domestic growth in this innovative industry and to support France’s leadership role within the European

Life Sciences community. More specifically, France Biotech acts as an engine of change by interacting with the government, economic organizations, academic institutions, the media and the investor community to ensure the prioritization of

the Life Sciences sector in France and the improvement of the economic, legal, regulatory and managerial environments for this important industry.



General Information

First French Biotechnology company: Cayla founded in 1977

Number of publicly-listed companies: 54 in December 2014 among which 27 on Euronext, 25 on Alternext and 2 on the Nasdaq

First publicly-listed company: Flamel Technologies in 1996, Genset in 1996 and Transgene in 1998

First French company listed on European stock exchange: Cerep on

the NYSE Euronext in February 1998

First company with FDA New Drug Application approval: Flamel

Technologies in December 2005

Most recent public listings: PIXIUM VISION on June 17, 2014; DBV

TECHNOLOGIES on October 22, 2014 on the NASQAQ

Number of French companies granted ‘Young Innovative Company’ status in 2013: 96 (vs. 93 in 2012) (Source: Panorama of the French Life Sciences Industry®, 2013)

Patents cliff: 10 « Blockbusters » with a revenue up to $1bn

concerned in 2013 (among which Eli Lilly’s « Cymbalta© », Biogen Idec’s « Avonex© », Merck’s « Rebif© », Roche’s « Xeloda© », Johnson & Johnson’s « Procrit© » and Amgen’s « Neupogen© »),

representing a revenue loss of $29bn. (Source : EvaluatePharma 2013)

27 new molecules with FDA approval in 2013 among which 6 stem

from biological products (vs. 39 with FDA approval in 2013 among which 9 stem from biological products) (Source: Nature biotechnology, vol 32,

number 2, February 2014)

BioAlliance Pharma is the first French Life Sciences company to

obtain the new drug marketing approval in the United States with the launch of Loramyc© known as Ovarig©.

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm381263.htm

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm381263.htm



Company Creations and Liquidations

(Source : France Biotech 12/31/2013)

In 2013, the Life Sciences sector showed its dynamism by generating a creation of 55 companies (+ 12% vs. 2012). This dynamism is stained by an increase in

companies’ liquidations since the sector suffers from 40 liquidations (+ 285% vs. 2012) during the same period showing the difficulty to persist in the sector.

Despite a crisis context, The French Life Sciences companies must pursue their efforts in terms of investments and innovation. For a large number of small and mid-size companies, there is no room for complacency since the prospects for

growth remain fragile; some of them had no choice but to shut down their activity.



Company Size

4,620 people in total are employed in this innovative sector making an average of 20 people per company in 2013 (vs. 4,150 people in 2012).

Company size in terms of number of employees in May 2013

(Source: Panorama of the French Life Sciences Industry 2013 - France Biotech)

133

36

36

9

0 20 40 60 80 100 120 140

From 1 to 10

From 11 to 30

From 31 to 99

100 and more

Number of companies

Nu

mb

er

of

em

plo

yee

s



Revenues

Biotech Pharma

Total revenues for the French biotechnology industry in 2013: €278 million (vs. €251 million in 2012) (Source : France Biotech Panorama 2013, n=214 companies surveyed)

Revenue of the 54 French publicly-listed companies in 2013: €575 million (vs. €524 million in 2012) (Source : France Biotech)

Total revenues for the French pharmaceutical industry in 2013: €53 billion (vs. €52.5 billion in 2012) (Source : Leem)

In 2013, revenues from medicines sold

in France were €26.7 billion, a

decrease of -1.67% from 2012 (Source : Leem)

Exports of medicine raise to €26.3 billion in 2013, an increase of +4.0%

from 2012 (Source : Leem)



Total R&D Expenses

R&D expenditures in biotechnology in 2012/2013:

Europe: 4.834 billion USD in 2013 vs. 5.020 billion USD in 2012 (Source: Beyond Borders Ernst & Young report 2014)

USA: 23.3 billion USD in 2013 vs. 19.4 billion USD in 2012 (Source: Beyond Borders Ernst & Young report 2014)

Canada: 315 million USD in 2013 vs. 360 million USD in 2012 (Source: Beyond Borders Ernst & Young report 2014)



List of the 10 most reimbursed drugs in 2013

(Source: PharmaGeek, April 2014)

Rank Product Therapeutic indication Company

Amount

reimbursed in

2013 (million)

Total evolution

2013 vs.2012

Rank in

2012

1 LUCENTISTreatment of wet age-related

macular degeneration (wAMD)Novartis €428.6 +10.2% 1

2 HUMIRATreatment of moderate to

severe rheumatoid arthritisAbbVie €382.8 + 10.6% 2

3 CRESTOR

Treatment for cholesterol-

lowering medicines called

statins

Astra-Zeneca €342.8 +1.4% 3

4 DOLIPRANETreatment for Fever, Muscle

Pain, Pain and SciaticaSanofi €315.0 +14.1% 5

5 ENBRELTreatment of moderate to

severe rheumatoid arthritisAmgen €278.1 +2% 6

6 SERETIDE Treatment of asthma GSK €274.8 -5.3% 4

7 LANTUS Antidiabetic Drug Therapy Sanofi €221.5 +8.6% 9

8 TRUVADA Treatmant for HIV Gilead Sciences €203.3 -1.5% 8

9 INEGY

Indicated as adjunctive

therapy to diet for use in

patients with primary

Merck €179.0 +4.4% 13

10 GLIVEC Treatment for cancer Novartis €178.8 +1.7% 11



Top 15 selling drugs 2013 vs. 2020

(Source: Evaluate Pharma, May 2014)

Product Company Therapy area 2013 2020e Year of first

launch

Sovaldi +

combo pill Gilead Sciences Hepatitis C therapy

0.14 13.12 2013

Humira AbbVie/Eisai Anti-rheumatic 11.02 12.57 2003

Lantus Sanofi Anti-diabetic 7.59 10.02 2000

Enbrel Amgen/Pfizer/Takeda Anti-rheumatic 8.78 8.58 1999

Remicade J&J/Merck/Mitsubishi Tanabe Anti-rheumatic 8.39 8.40 1998

Januvia +

Janumet Merck & Co Anti-diabetic

5.83 6.89 2006

Avastin Roche Cancer antibody 6.75 6.57 2004

Xarelto Bayer/J&J Anti-coagulant 1.95 6.44 2008

Nivolumab Bristol-Myers Squibb/Ono Cancer antibody – 6.33 TBC

Revlimid Celgene Immunomodulator 4.28 6.23 2006

Prevnar 13 Pfizer Vaccine 3.86 6.03 2009

Tecfidera Biogen Idec Multiple sclerosis 0.88 5.74 2013

Rituxan Roche Cancer antibody 7.50 5.61 1997

Eylea Regeneron/Bayer/Santen Macular

degeneration

2.03 5.59 2011

Soliris Alexion Pharmaceuticals

Rare

haematological

conditions

1.55 5.12 2007

Top 15 selling drugs in 2020

Global sales ($bn)



Top 10 worldwide fundraisings in 2013

(Source: Evaluate Pharma, World Preview 2014, Outlook to 2020, October 2014)

Company Country Industry Type Operation DateTotal Amount

($m)

Intrexon US Biotech mai-13 150

Juno Therapeutics US Biotech déc-13 120

Moderna Therapeutics US Biotech nov-13 110

Symphogen Denmark Biotech mai-13 98

Ganymed Pharmaceuticals Germany Biotech nov-13 64

PTC Therapeutics US Biotech mars-13 60

Arrowhead Research US Biotech oct-13 60

Intra-Cellular Therapies US Biotech sept-13 60

Dicerma Pharmaceuticals US Biotech août-13 60

Trevena US Biotech mai-13 60



Publicly-listed biotechnology companies

Source: France Biotech, June 2014

7 new public listed companies in 2013 for a total amount raised of 153 €m, which represents an increase of 5% (vs. 2012). In S1 2014, 9 new public listed companies have already been registrated, in the French stock exchange, for a

total amount of 237 €m.

2014 10 IPOs

DBV Technologies (Nasdaq) => €90m

SuperSonic Imagine => €50m

Fermentalg => €40.4m

Pixium Vision => €34.7m

Genticel => €34.5m

Genomic Vision => €20.3m

Crossject => €17.4m

TxCell => €16.2m

Oncodesign => €12.8m

Theraclion => €10.9m

2013 7 IPOs

LDR (Nasdaq) => €75m

Medtech => €20m

Erytech Pharma => €17.7m

Implanet => €14.1m

Carbios => €13.1m

Spineguard => €8.1m

Spineway => €4.9m



AB Science:

Date of IPO: April 26th, 2010

Funds raised from IPO: €16.5 million

Share price at entry: €12.65

Price on December 29th, 2014*: €11.60

Market Capitalization on December 29th, 2014: €339 million

Adocia:

Date of IPO: February 14th, 2012





Biosynex:

Date of IPO: March 21st, 2011





Carbios:

Date of IPO: December 19th, 2013





Carmat:

Date of IPO: July 13th, 2010

Funds raised from IPO: €16 million



Market Capitalization on December 29th, 2014: €284 million9s

Cellectis:





Market Capitalization on December 29th, 2014: €348 million * Close

Source: Les Echos Bourse



Crossject:

Date of IPO: February 2014





DBV Technologies (NASDAQ, NYSE):

Date of IPO (NYSE): March 28th, 2012

Date of IPO (NASDAQ): October 22nd, 2014

Funds raised from IPO (NYSE): €40 million

Funds raised from IPO (NASDAQ): €90 million

Share price at entry (NYSE): €8.86

Price on December 29th, 2014* (NYSE): €43.70

Market Capitalization on December 29th, 2014 (NYSE): €839 million

Deinove:

Date of IPO: April 2010





Diagnostic Medical Surgical:

Date of IPO: 1998

Price on May 31, 2013: €0.23

Market Capitalization on May 31, 2013: €17.12 million



Diaxonhit:

Date of IPO: November 17th, 2005





EOS imaging:








ERYTECH Pharma:

Date of IPO: May 7th, 2013





Fermentalg:


Funds raised from IPO: €40.4 million Share price at entry: €7.30



Flamel Technologies (NASDAQ):

Date of IPO (Nasdaq): 1996

Funds raised from IPO: $26.6 million

Share price at entry: $12

Price on December 26th, 2014: $17.12

Market Capitalization on December 26th, 2014: $661 million

Genfit:

Date of IPO: December 19th, 2006





Genomic Vision:




Prix on December 29th, 2014*: €10.90


Genoway:





Market Capitalization on December 29th, 2014: €12 million * Close

Source: Les Echos Bourse



Genset :

Date of IPO: June 6th,1996 (Nasdaq and Paris Bourse)


Acquired in 2002 by the Swiss biotechnology company Serono

Serono was pursached in 2006 by the German drug company Merck to give birth to the Merck Serono Group

Genticel:



Share price on April 14, 2014: €6.60

Market Capitalization on April 14, 2014: €100 million



Global Bioenergies:

Date of IPO: June 9th, 2011





Hybrigenics:

Date of IPO: December 2007





Implanet:






* Close Source: Les Echos Bourse



Innate Pharma:

Date of IPO: November 2006





Integragen:






Intrasense:

Date of IPO: February 22nd, 2012





LDR (NASDAQ):

Date of IPO (Nasdaq): October 9th, 2013

Funds raised from IPO: $75 million

Share price at entry: $15

Price on December 26th, 2014: $35.98

Market Capitalization on December 26th, 2014: $343 million

Mauna Kea Technologies:



Share price at entry: €13



MedianTechnologies:









Medicrea international:

Date of IPO: June 23rd, 2006





Medtech Surgical:






Metabolic Explorer:






Nanobiotix:

Date of IPO: October 29th, 2012





NeoVacs:






Nicox:

Date of IPO: November 3rd, 1999


Share price at entry au June 19, 2002: €15.05






Novacyt:






Olmix :

Date of IPO: March 29th, 2005



Price on December 24th, 2014: €5.19


Oncodesign:

Date of IPO: March 28th, 2014


Share Price at entry: €7.34

Market Capitalization on March March 28, 2014: €65 million



Onxeo (former BioAlliance Pharma):

Date of IPO: August 2014





Pixium Vision :




Market Capitalization on June 17th, 2014: €100 million






Qiagen Marseille:






Quantel:

Date of IPO: 1997



Quantum Genomics:

Date of IPO: April 10th, 2014 (transferred its shares to Alternext Paris)



Spineguard:

Date of IPO: April 23rd, 2013





Spineway:






Stallergenes:

Date of IPO: 1998






Stentys:

Date of IPO: October 22nd, 2010





SuperSonic Imagine:




Market Capitalization on April 10, 2014: €182.6 million



Theraclion:




Market Capitalization on May 02, 2014: €54.5 million



Theradiag:

Date of IPO: December 2012





Transgene:

Date of IPO: 1998








TxCell:






Valneva:

Date of IPO: June 2007





Vexim:






Visiomed Group:









NEXT BIOTECH INDEX: 1,442.16 ON DECEMBER 29TH, 2014*

Source: Euronext 12/27/2013 - 12/29/2014

Market Capitalization of the 54 French Life

Sciences companies on December 29th

, 2014**

8.16 Billion Euro

* Close ** Source: Les Echos Bourse



Distribution of French Life Sciences

companies publicly-listed by Industry Sector

Biotech (19) Medtech (22) Diagnostic (7) Greentech (6)

AB Science Carmat Biosynex Carbios

Adocia Crossject Diaxonhit Deinove

Cellectis Diagnostic Medical Surgical Genomic Vision Fermentalg

DBV Technologies EOS imaging Integragen Global Bioenergies

Erytech Pharma Implanet Novacyt Metabolic Explorer

Flamel technologies Intrasense Qiagen Marseille Olmix

Genfit LDR Theradiag Genoway Mauna Kea Technologies

Genticel Median Technologies Hybrigenics Medicrea International Innate Pharma Medtech Surgical Neovacs Nanobiotix Nicox Pixium Vision Oncodesign Quantel Onxeo Spineguard Quantum Genomics Spineway Stallergènes Stentys Transgène SuperSonic Imagine TxCell Theraclion Valneva Vexim

Visiomed Group

Source: France Biotech, September 2014



Fundraising by French Biotech companies

Source : France Biotech, June 2014

Funds raised* in 2009: 270 million Euro

Funds raised* in 2010: 472 million Euro (+ 75% vs. 2009)

Funds raised* in 2011: 287 million Euro (- 39 % vs. 2010)



Funds raised* in H1 2014: 623 million Euro

Creation of AURIGA IV Bioseeds (October 2013): this fund was created

to encourage company creations, focussing on projects initiated from

scientific knowledge and expertise in Infectiology and Microbiology. With

a first closing at 40 million Euro, AURIGA IV Bioseeds has an average

duration of life of twelve years and relies on its close collaboration with

industrial and institutional partners.

Creation of the Innovative Biotherapies and Rare Diseases Fund

(May 2013**): with a closing at 50 million Euro, this fund focuses on seed

financing for companies developing innovative biotherapies and rare

diseases.

* Fonds levés = capital-risque + montant de la levée lors de l’IPO + refinancement en Bourse

** Source : http://www.bpifrance.fr



2014

Venture Capital Funding*

AAVLife raised $12 million (8.6 million Euros) in a series A financing,

from Versant Ventures and Inserm Transfert Initiative. The fund

raising should allow the a gene-therapy company to advance into

clinical studies the work on Friedreich’s ataxia.

Advanced Accelerator Applications raised 41 million Euros from

HBM Healthcare Investments Ltd.

Aelis Farma, announced a fund raising of 1,3 million Euros Inserm

Transfert Initiative and two regional funds: Aqui Invest and Aquitaine

Création Investissement.

Alizé Pharma, biotechnology company developing treatments for rare

diseases and metabolic diseases, has signed a new round of 5 million

Euros.

Alzprotect raised 2 million Euros from several business angels and

two investment funds, Finovam and Nord France Amorçage so as its

historical shareholders.

Amoéba raised 3 million Euros from Siparex Proximité Innovation,

which re-invested 1 million Euros, and other historical investors

among which: Rhône-Alpes Création for €400,000, Eurékap! and

Evolem. CM-CIC-capital privé invested €700,000 as a new investor.

Atlanthera raised 0,8 million Euros from GO CAPITAL Amorçage.

Biosantech, company specialized in AIDS therapy, raised 0.8 million

Euros with crowdfunding platform Happy Capital.

Caviskills, biotechnology company, raised 0.4 million Euros.

Celenys raised 1 million Euros from GO CAPITAL which invested

€700,000 and NCI as a co-investor of amount of €300,000.

CellProthera, company specialized heart diseases, raised 5 million

Euros from three historical investors.

*Source: Biotech Trade, Companies’ press releases, France Biotech, 2014



Enterome raised 10 million Euros in B round led by existing investors

Seventure and Lundbeckfond Ventures. Existing investor Omnes

Capital also participated.

Fab’entech, a biotechnology company which develops anti-infective

immunotherapy treatments, raised 5 million Euros from Auriga

Partners, R2V, Rhône-Alpes Creation, Sigma Gestion and several

other entrepreneurs who invest in a private capacity.

GamaMabs Pharma raised 1.1 million Euros (0.5 million Euros from

Alto Invest + 0.6 million Euro from bpifrance as a repayable advance).

GenSight Biologics raised 3 million Euros from bpifrance via its fund

dedicated to innovative biotherapies and rare diseases.

Hemarina raised 4 million Euros from CM-CIC Capital Innovation

which invests 3 million Euro. Finistère Angels, the historical

shareholder, Armor Angels and et Business Schools Business Angels

invested 1 million Euros.

Horama, spin off of UMR1089 of Nantes and UMR of Montpellier

raised 450,000€ from 3 entrepreneurs (Simone Bougro from Sodebo,

Joël Soulard from Ernest Soulard and Denis Cayet, the founder of

Horama).

Hyprevention, a medical device company, raised 3 million Euros

from Helvesta AG.

ImmuSmol raised 500,000€ for the development of its

immunotherapy program.

In2Bones raised 3 million Euros from Newfund.

InFlectis BioScience raised 1 million Euros from the family holding

Participations Besançon and GO Capital, in order to finance its in vivo

studies. InFlectis BioScience is a young innovative biotech company

from Nantes, France, created in 2013. Its main activity consists in the

identification of therapeutic molecules for the treatment of neuro-

degenerative diseases or aging diseases.

InnaVirVax should receive 6.3 million Euros from the 9.4 million Euro

invested by bpifrance in the anti-AIDS vaccine candidate VAC-3S

which is part of the ProtheVIH program.



Inotrem announced a fund raising of 18 million Euros from two

venture capital funds: Edmond de Rothschild Investment Partners and

Sofinnova Partners the representatives of which have joined the

Board of Inotrem. BioMed Invest and Inserm Transfert Initiative had

participated to the operation as well.

Leosphere raised 20 million Euros from Oraxys, a leading European

cleantech private equity firm for an investment exceeding €10 million.

LNC raised 1.5 million Euros from Seventure, 900,000€ of which is

from the Health for Life Capital fund. The financing will enable LNC, to

complete the clinical development of its two main products in pre-

diabetes and bariatric surgery.

Lysogene, company specialized in genetic therapy, raised 16.5

million Euros from Sofinova Partners, Innobio and Novo Seeds.

ManRos Therapeutics raised 3,6 million Euros from several long-

term shareholders.

Mathym, a young innovative company focusing on nanotechnologies,

raised 8,3 million Euros from Bpifrance.

MDoloris Medical Systems raised 1,1 million Euros from Siparex

Proximité Innovation and Finorpa.

Medtech Surgical, company specialized in robotic surgery, raised 8.3

million Euros from bpifrance.

Microphyt raised 2 million Euros from CEA Investissement (Fund:

Amorçage Technologique Investissement), Sofimac Parteners (Fund:

Emergence innovation 1), Soridec and Jeremie LR.

NG Biotech raised 1 million Euros thanks to the support of Kreizig

Fund.

Nutrivercell raised 0.5 million Euros from Scientopole Capital, XMP

Business Angels, Paris Businesss Angels, Angels Santé, Trianon

Angels, Cap initial Harvard Angels France.

OCR completes its first fund raising with more than 1 million Euros

from Nord France Amorçage and A&S (« Autonomie et Solidarité »)

combined with the participation of some business angel’s.



Ose Pharma achieved its first fund raising at 3.2 million Euros from

Sigma Gestion and Financière Tuileris Développement.

Poxel, Lyon Biopharmaceutical Company specialized in the

development of new oral drugs for Type II diabetes, raised 10 million

Euros with a stake in Bpifrance through its pole Large Venture and a

loan from Kreos Capital. The cumulative amount of the Series B

financing, initiated by Edmond de Rothschild Investment Partners

(EdRIP), stands at 18 million Euros.

Prestodiag, diagnostic company, raised 2.2 million Euros from CEA

Investissement, Cap Décisif Management, Kreizig Invest and Go

Beyond Network.

Rhenovia Pharma completed a fund raising of 0,54 million Euros

from its historical shareholders.

SP3H raised 2.5 million Euros from Truffle Capital, his historical

shareholder which has already participated to the other two

fundraising rounds for a total amount of 7 million Euros.

Tesalys raised 1 million Euro from Entrepreneur Venture.

Theranexus completed a fundraising of 3.6 million Euros from Auriga

Partners, CEA Investissement, Emergence Innovation 1 and Rhône-

Alpes Creation.

Valwin succeeded in raising 320,000€ from PE Investments and

Bpifrance.

Vect-Horus raised 1.5 million Euros from its historical shareholders.

The French life science company from Marseille designs and

develops peptide vectors that facilitate the delivery of drugs or

imaging agents.

Ynsect raised 1.8 million Euros as a first fund raising from two eco-

technologies venture capital funds known as EMERTEC Gestion and

DEMETER Partners.

Ynsect has raised 5.5 million Euros from New Protein Capital. The

financial company based in Singapore has joined Ynsect’s historical

investors to the Board and came as a first step of the future

international development of the French start-up, especially in Asia.



2013


Advanced Accelerator Applications succeeded in a fund raising of

4.8 million Euros from historical and new investors among which

Seventure Partners.

Allecra Therapeutics suceeded in its first funding round for an

amount of 15 million Euros from BioDiscovery 4, the four ranked of

Edmond de Rothschild Investment Partners’ Fund.

Aqualeg raises 0,55 million Euros from GO Capital.

Aterovax raised 1.5 million Euros from Turenne Capital and Fa dièse.

Axess Vision Technology raised 3.5 million Euros from Viveris

management and Sofimac Partners.

Axilum Robotics raises 0,85 million Euros from Inserm Transfert

Initiative SODIV Alsace.

Azimut Monitoring raises 0,43 million Euros among which more than

€350,000 from Savoie Angels.

Bioaxial raised 1.9 million Euros from Amorçage Technologique

Investissement (managed by CEA Investment), Inserm Transfert

Initiative, Viveris Management and individual investors.

BioSIMS raised 1.14 million Euros from GO CAPITAL (900,000€) and

Normandie Business Angels, Norm’Angels and Scientific Analysis

Instruments (239,000€).

Bodycap raises 0,4 million Euros from GO Capital.

C2F Implants raises 2.5 million Euros from Audacia.

CellProthera confirmed a third fund raising of 2.54 million Euros from

two « family funds ».




Coldway succeeded in a fund raising of 9.3 million Euros from

Ecotechnologies fund, Emertec Gestion, CM-CIC Capital Innovation,

Sudinnova and historical investors.

CrossJect raises 4.6 million Euros from A Plus Finance, Sofimac

Partners and Gemmes Venture.

Defymed raised 1.2 million Euros as part of the development of an

innovative bio-artificial pancreas thanks to the Materials Lorrain Fund.

Dialpha completes a fund raising of 1 million Euros.

Ecoat completes a 1.5 million Euros fund raising in order to settle a

production facility and to launch its innovative product line.

ElsaLys Biotech raises 2.1 million Euros from Transgene.

EndoControl raises 4 million Euros from CM-CIC Capital Innovation,

Seventure Partners and Viveris Management, in order to speed up its

technological and commercial development.

Eydo Pharma raised 1 million Euro from Sofimac Partners.

EyeTechCare completes its third financing round from historical

investors for a total amount of 10 million Euros.

Fermentalg raised 12 million Euros from IRDI, Viveris Management

and Emertec gestion, Demeter Partners, ACE Management (Atalaya),

Picoty Algo Carburant and Sofiproteol as historical investors.

Fluoptics raised 2 million Euros through Viaducs’ participation.

France Perfusion raised 500,000€ from MIDI Capital in order to

pursue its development.

GamaMabs Pharma raises 3.1 million Euros from bpifrance through the fund Innobio, as addition to IRDINov and IXO Private Equity.

Gecko Biomedical announces a fund raising of 8 million Euros as an

A financing round from CM-CIC Capital Finance, Omnes Capital and CapDécisif Management.

Gensight Biologics raised 32 million Euros from Novartis Venture

Fund, Abingworth, Versant Ventures and Index Ventures.



Genticel announces a fund raising of 18.2 million Euros from

Wellington Partners (Munich, Germany) and from all the current institutional investors such as: IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), Innobio, IRDI and Amundi

Private Equity Funds.

I2A raised 1.5 million Euros from MIDI Capital and Soride.

IDD Biotech succeeded in its first funding round worth 1.5 million

Euros.

ImmunID announces a fund raising of 2.4 million Euros from 3

investors: Vizille Capital Innovation, SOFIMAC Partners and CEA

Investment.

Ledpower completes its second fund raising of 0,92 million Euros.

Lentilles – LCS completed a new fundraising of 500,000€ from GO

Capital.

MedDay raises 8 million Euros from InnoBio and Sofinnova Partners.

Medtech completes a fund raising of 4.5 million Euros among which

1.5 million Euro from MIDI CAPITAL.

Neuronax completes a 1 million Euros fund raising from Jérémie

Innovation 1 managed by SOFIMAC Partners, Fa Dièse 2, Wiseed

and Auvergne Business Angels.

PathoQuest, succeeded a second fund raising round for a total

amount of 3.8 million Euros from two new investors Idinvest Partners

and Aurinvest Capital jointly with the historical investor Kurma

Biofund.

Physikron raised 160,000€ from CAP Decisif Management.

Pixium Vision raised 15 million Euros from Sofinnova and Omnes

Capital.

Poxel completes a second fund raising for an amount of 13 million

Euros from Edmond de Rothschild Investment Partners and the

historical investors, Innobio fund and Omnes Capital.



Robocath gets 0,9 million Euros from GO Capital (€600,000) and NCI

Gestion (€300,000).

Sensorion raised 2 million Euros from Innobio and Inserm Transfert

Initiative.

Spinevision completed a fundraising of 7.78 million Euros from MIDI

Capital, Omega Funds and Alto Invest.

Sunpartner Technologies completes the first part of a 3.1 million

Euros, the amount of which will reach 8 million Euros in the first

semester of 2014.

SuperSonic Imagine closes a fund raising of 28 million Euros from

the Strategic Investment Fund, Alto Invest and KLSC (Kuwait Life

Science Company).

Synthélis raised 0.6 million Euros from Savoie Angels and Grenoble

Angels.

Theravectys raised 14.7 million Euros from Tethys with the help of La

Financière (a Philippe Oddo’s company), FGP Capital and other

private investors.

Vetbiobank completes a fund raising of 0,385 million Euros from

Health Angels Rhône-Alpes (Hara), Simba Santé and Angelor.

Wandercraft closes a financing round table for an amount of 0,6

million Euros from Kima Ventures (€300,000), CMG Advisory

(€100,000) and private investors (€200,000).



2012


Alize Pharma raised 3.1 million Euros from Octalfa S.A.S., CEMA Inc.,

Sham and private investors.

Amoeba raised 800,000€ from Rhône-Alpes Création, Eurekap!, Siparex and Dancer family.

Arterial Remodeling Technologies raised a fundraising of 2.21 million

Euros.

Aterovax raised 1.2 million Euros from Fa Dièse and Turenne Capital

Biofilm Control raised 3 million Euros from Sofimac Partners,

Entrepreneur Ventures and Merieux Institute.

Biom’up raised 6.8 million Euros from InnoBio, Viveris Management,

OTC Asset Management, Mérieux Développement, SHAM, Sofimac Partners, Aquasourça and l’Améliane.

Biophytis raised 2 million Euros during a second round of financing with Metabrain Research, Seventure Partners and CM-CIC Capital

Privé.

Calixar raised 875,000€ from Siparex, Veymont Participations, INPG

Entreprise SA and Business Angels.

Carbios raised 3.3 million Euros from Truffle Capital.

Carlina Technologies raised 300,000€ from Go Capital.

Crossject raised 4 million Euros

Cytune Pharma completed a fundraising of 1 million Euro from Sodero,

Idee, Remora Capital and Starquest Capital

Diafir raised 300,000€ from Grand Ouest CAPITAL

Domain Therapeutics raised 2 million Euros, the half of which comes from Seventure Partners and the other half from SODIV and historical investors that include AIRFI, IP Growth, Auriga and Sam Eletr, the

Chairman of the company’s Board.




Echodia raised 250,000€ from Sofimac Partners

Enterome Biosciences raised 5 million Euros from Seventure Partners

and Lundbeckfond Ventures in an A funding round.

Exonhit raised 6.1 million Euros from institutional investors in

November.

EyeBrain raised 3.3 million Euros from Octalfa, Sudinnova and CM-CIC Capital Innovation to develop its Marketing and Sales activity.

Eyevensys raised 1.6 million Euros from InnoBio, Inserm Transfer Initiative and a private investor.

Hemarina raised 6.3 million Euros from Inserm Transfert Initiative,

Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement

ICDD raised 800,000€ from Grand Delta Angels, SRC CDPS, Var

Business Angels and Turenne Investments

Imaxio raised 2.9 million Euros from Pradeyrol Development.

InnaVirVax raised 3.7 million Euros during a B round with Pradeyrol Développement, Fa Dièse, FRCI (Fonds Régional de Co-Investissement d’Ile-de-France), CapDecisif 2 and G1J Ile-de-France.

Koelis raised 1 million Euro from Medevice Capital

LNC raised 3.5 million Euros from Seventure, IRDI, GSO Capital and

Aqui-Invest

Medtech raised 555,000€ from Soridec and Jeremie

Neosteo completed a fundraising of 800,000€ from Go Capital, Pays de

Loire Développement and IDEE

Novacyt raised 1.5 million Euros from private investors and ARKEON

Gestion.

Nutrivercell raised 446,000€ from XMP-Business Angels, Angels Santé, Capintial, Trianon Angels, Harvard Business School Club de France, Paris Business Angels and Scientipôle Capital.

Olea Medical raised 4.2 million Euros from INNOVACOM.

Pharnext raised 8 million Euros closing a private placement terms.



Pixium Vision raised 19 million Euros from Omnes Capital and other

investors.

Poxel SA raised 13 million Euros in a B round financing with Edmond

de Rothschild Investment Partners, InnoBio, and Omnes Capital.

Pro Tip SAS raised 3.8 million Euros from Seventure Partners, Fonds

Lorrain des Matériaux (FLM), the family office Berchet and Alsace Amorçage

Provepharm completed a fundraising of 2.7 million Euros from Viveris

Management, Sofipaca, Paca Investissement and private investors.

Sensorion raised 750,000€ from Innobio

SP3H raised 2.2 million Euros from Truffle Capital

Theravectys raised 7.48 million Euros from private investors that

included Guy PAILLAUD, John PIETERS, the BETTENCOURT family, Philippe ODDO and Richard HENNESSY.

TxCell raised 12.7 million Euros from InnoBio, Auriga Partners and Seventure Partners.

Vectalys succeeded in a fundraising of 1.2 million Euros from Fadièse2,

FJ investissement and a business angel.



2011


Advicenne raised 3 million Euros in May during a second round

financing from InnoBio, Ixu Private Equity and private investors.

Cellprothera raised 2.5 million Euros from R2M and SODIV ALSACE.

Cytoo Cell Architects raised 7 million Euros from Sham, Entrepreneurs

Fund, Auriga Partners and Jacques Lewiner.

DBV Technology raised 19.4 million Euros from Innobio, Lundbeckfond

Ventures, Shire plc, Alto Invest, Sofinnova Partners and ALK Abello.

Ethera raised 1.2 million Euros from CEA Investissement and Emertec Gestion

Eviagenics raised 1.3 million Euros from CEA Investissement, Emertec and Cap Decisif Management

Fermentalg raised 5.3 million Euros from Emertec, ACE Management,

Demeter Partners, CEA Investissement, Aquitaine Création Investissement and Groupe Picoty.

Genfit raised 5.3 million Euros from YA Global Master SPV Ltd.

Graftys raised 4 million Euros from Ventech, Octalfa S.A.S.,Viveris Management and Oreo Finances Corp.

Kreactive raised 5 million Euros from Emertec and Demeter

Multix succeeded in raising 3 million Euros

Neovacs received 2.3 million Euros from Truffle Capital, Debioinnovation and OTC Asset Management.

PathoQuest raised 2 million Euros from KurmaBioFund

Pharnext raised 2.5 million Euros from Truffle Capital, La Financière Gaspard and Parinvest.

Polyplus Transfection raised 2.5 million Euros from Alsace Inter

Region Fonds d’investissement, Sudinnova, CIC Vizille Capital Innovation and CIC Finance




Mergers and Acquisitions in France and

Europe In 2013, there were 30 mergers/acquisitions in Europe in the biopharmaceutical

sector for a total value of 22.2 billion USD (vs. 22 deals for 10.4 billion USD in 2012) compared with 40 mergers/acquisitions for a total value of 27.1 billion USD in the USA (vs. 48 deals for 32.5 billion USD in 2012).

Top 10 Mergers & Acquisitions in the Life Sciences sector worldwide (Source: HBM Pharma/Biotech M&A Report 2013)

Biggest Mergers & Acquisitions by European countries (Source: HBM Pharma/Biotech M&A Report 2013)

Acquisition Amount ($bn)

Onyx (US) - Amgen (US) 10 400

Bausch & Lomb (US) - Valeant (Canada) 8 700

Elan Corp (Ireland) - Perrigo (US) 8 600

Warner Chilcott (Ireland) - Actavis (US) 8 500

Pearl Therapeutics (US) - AstraZeneca (UK) 1 150

Aragon Pharmaceuticals (US) - Johnson & Johnson (US) 1 000

Map Pharmaceuticals (US) - Allergan (US) 958

Pronova (Norway) - BASF (Germany) 900

Astex (US) - Otsuka (Japan) 886

Trius Therapeutics (US) - Cubist Pharmaceuticals (US) 812

Target Company Country Buyer Country Total Deal Value ($m) Therapeutic Area(s) of Target Company

Pearl Therapeutics US AstraZeneca UK 1 150 Respiratory diseases

Pronova Norway BASF Germany 900 Nutritional Health

Xellia Pharmaceuticals Norway Novo A/S Denmark 700 Infectious diseases

Amplimmune US AstraZeneca UK 500 Immune System, Oncology

Doc Generici Italy Charterhouse UK 450 Generics

Acino Switzerland Pharma Strategy Sweden 450 Drug delivery

Omthera US AstraZeneca UK 443 Cardiovascular

Spirogen UK AstraZeneca UK 440 Oncology

Thornton Ross UK Stada Germany 345 Over-the-counter medicines

Okairos Switzerland GSK UK 323 Oncology, HIV

Ceptaris US Actelion Switzerland 250 Oncology

Acton Pharmaceuticals US Meda Sweden 200 Respiratory diseases

SARcode US Shire Ireland 160 Ophtalmology

Intercell Austria Vivalis (Valneva) France 130 Vaccines

Laborarotios Casen Fleet Spain Recordati Italy 120 Gastroenterological



Recent Operations*

2014

o Adocia has completed a partnership agreement with the

pharmaceutical company Eli Lilly to develop ultra-rapid insulin (the

BioChaperone Lispro), for treatment in people with type 1 and type 2

diabetes. Under the terms of the agreement, the French Life Science

company will receive a total upfront fee of $50 million (€40.6 million)

with the potential for future payments of up to $280 million (€228

million) if the product reaches certain development and regulatory

stages.

o BioAlliance Pharma and Topotarget announced their intention to

merge to create a leading orphan oncology company, named Onxeo,

with highly complementary pipelines of late-stage products addressing

significant unmet medical needs.

o BioAlliance Pharma announced that the FDA had granted its

treatment of patients with refractory peripheral T-cell lymphoma

developed by Topotarget.

o Cardio3 Biosciences completed a fundraising of 25 million Euros on

June 6th, 2014.

o Cardio3 BioSciences has enrolled its 120th patient in its phase III

clinical study CHART-1.

o Cardio3 BioSciences announced the acquisition of CorQuest Medical

Inc., a US-based company specialized in the development of

innovative devices and technologies for cardiac surgery.

o Carmat has received 5 million Euros in repayable advances due to the

completion of milestone n°5 of the contract for industrial strategic

innovation signed in 2009 with Bpifrance. According to the terms of the

contract, the completion of milestone n°5 was depending on “the

qualified production of implantable prostheses and the monitoring of

technical and medical criteria associated with the first clinical

implants”.

o Cellectis announced the selling of its branch Cellectis AB to the

japanese company Takara Bio Inc. *Source: BiotechTrade, companies press releases (websites)



o DBV Technologies completed successfully its entry in the Nasdaq.

The French biotech company raised 90 million Euros in order to

improve its R&D.

o Deinove signed a contrat with Sofiprotéol which includes a

collaboration of 3 years in order to develop a production line of natural

additives for animal feeding.

o Deinove completed a new fundraising with a participation of Truffle

Capital up to 2 million Euros.

o Deinove has established a new equity line funding with the company

KEPLER CHEUVREUX. The French cleantech company has the

guarantee to be able to raise a maximum amount of 15 million Euros

in four tranches over three years.

o EOS imaging extended its presence worldwide with the installation of

EOS® in Australia. The imaging system will be installed in two

Australian medical facilities: the Royal Children’s Hospital Melbourne

(RCH) and at Southern Radiology in Sydney.

o EOS imaging announced that the Korean Food and Drug

Administration (KFDA) had granted clearance for the

commercialization of EOS® system in South Korea.

o EOS imaging obtained the approval from the FDA for hipEOS, a 3D

hip arthroplasty planning software based on EOS stereo-radiographic

2D/3D imaging.

o ERYTECH Pharma reported positive Phase III results on the use of

GRASPA®.

o ERYTECH Pharma announced the granting in the USA of a new

patent in the field of asparaginase.

o ERYTECH Pharma completed successfully a fundraising of 30 million

Euros. The French life science company will expand its therapeutic

indications in oncology and accelerate its clinical developments.

o Genfit announced the allowance in China of a patent for GFT505, its

leading drug candidate, in NASH and hepatic fibrosis.



o Cellectis has completed a non-exclusive cross-license agreement

with the Two Blades Foundation relating to TAL nuclease

technologies. Under the terms of the agreement, Cellectis plant

sciences receives a license under 2Blades’ TAL Code technology

related to nucleases for commercial uses in certain specified crop

plants.

o Genfit raised 21 million Euros from US institutional investors. The

private placement was made through the sale of 583,433 shares at

€35.95.

o Hybrigenics reported a fundraising of 4.62 million Euros from Crede

Capital Group.

o MDxHealth succeeded in a fundraising of 12 million Euros.

o Median Technologies has been chosen by some Big Pharma

companies in order to conduct 3 new studies. The French life science

company will provide imaging services solutions which represent a

total amount of 1.58 million Euros.

o Medicrea announced that the FDA clears world’s first patient-specific

pinal rod UNiD™.

o Medtech has received official authorization to sell the ROSA™ on the

Chinese market. The Brain surgical device will be delivered by the

Chinese company Beike Digital Medical Technology specialized in the

distribution of neurological and Brain medical devices.

o METabolic EXplorer signed an agreement with SK CHEMICALS, a

south-korean green chemicals company. The agreement concerns the

production and the commercialiazation of PDO (1.3-propanediol) using

the technology developed by METabolic EXplorer.

o MyoKardia signed a collaboration agreement with the French drug

company Sanofi in order to develop targeted therapies for patients

with genetic heart disease.

o Nanobiotix strengthened its collaboration with its partner

PharmaEngine, Inc. with the update of the development plan for

NBTXR3 in order to obtain faster market authorization in the Asia-

Pacific region.



o Nanobiotix raised 10.39 million Euros from Capital Ventures

International, a US investor via a private placement of new shares with

subscriptions warrants. In case of the exercise of all the warrants, the

issue may be increased by up to 14.06 million Euros.

o Nanobiotix has received approval from the French National Security

Agency for Medicines and Health Products (ANSM) to start its Phase

II/III registration trial of NBTXR3. The product has the ambition to

improve the efficacy of radiotherapy by “destroying locally advanced

tumors more efficiently”.

o Neovacs closed a strategic agreement with the German life science

company Pharmedartis for the supply of interferon alpha (IFN-alpha)

as part of its phase IIb study with the IFN-alpha-Kinoïde therapeutic

vaccine for the lupus treatment.

o Nicox signed an exclusive agreement with OptiMed, an Australian

company distributing ophthalmic diagnostic and therapeutic products.

The agreement plans the distribution of Nicox’s product portfolio in

Australia and New Zealand.

o Nicox launched the Xailin Gel in Europe, a multidose carbomer gel

lubricant that becomes preservative-free in the eye. Xailin Gel is a

medical device, the third one following Xailin Night and Xailin Fresh.

o Nicox announced its agreement to acquire U.S. company Aciex

Therapeutics Inc, specialized in the ophthalmic sector and holding a

pipeline of several drug candidates in an advanced development

stage. The operation would include a $65 million (47.5 million Euros)

upfront payment in newly issued Nicox shares, in addition to

contingent value rights giving right to shares worth up to $55 million.

o Nicox plans to acquire 100% of shares Doliage, a French company

specialized in ophthalmology, for 5 million Euros.

o Nicox announced the acquisition of its diagnostics US subsidiary

Nicox Inc., by the Canadian drug company Valeant Pharmaceuticals

International, Inc. The deal worth up to $20 million (16 million Euros)

and follows the strategy of Nicox to concentrate its commercial and

development resources on ophthalmic therapeutics.



o Nicox acquires all the rights of antiviral eye drops containing

Carragélose® Marinomed Biotechnology for the potential treatment

of viral conjunctivitis, for 5.3 million Euros.

o Novacyt has reached an agreement with the British company Lab21

seeking for a capital increase. Lab21 is now a total subsidiary of

Novacyt with a capital sharing as following: 54% for the current

shareholders and 46% for Lab21 shareholders.

o Oncodesign signed an agreement with Isarna Therapeutics GmbH

in order to conduct in vivo pharmacology studies to investigate the

potential of TGF-β therapeutics. TGF-β stimulates the human immune

system to effectively fight cancer, ocular diseases and fibrosis.

o Onxeo has received a milestone payment of $25 million (20 million

Euros) from Spectrum Pharmaceuticals, his US partner. The payment

is related to the approval of Beleodaq® by the FDA, in July 2014.

o Onxeo received a payment of 1.25 million Euros from BpiFrance as a

part of the funding granted to support the NICE (Nano Innovation for

Cancer), the first consortium of nanomedicine stakeholders.

o Onxeo started a rights issue in a bid to raise 41.6 million Euros in

order to improve its R&D efforts. The Franco-Danish biotech company

plans to become a main actor in orphan drugs in oncology.

o Onxeo completed successfully a 40.7 million Euros capital increase

with preferential subscription rights launched both in France and in

Denmark on November 17th, 2014.

o OSE Pharma has registered with market regulator AMF for an initial

public offering (IPO).

o Pharnext announced the proof of concept of its pleotherapy research

and development approach based on a proprietary network

pharmacology platform that identifies synergic combinations of drugs

already approved for other diseases.

o Stallergenes exercised option to pursue the exclusive development of

application of ActoGeniX's technology for targeted delivery of allergen-

based treatments



o Stentys announces the acquisition of the American company

Cappella Peel Away Inc. (Delaware, US) and, therefore, of its assets

relating to a novel stent delivery system. This technology is CE

marked in Europe and has been clinically validated. Terms were not

disclosed.

o Stentys won a large regional tender in the Middle East awarded more

than 1,000 coronary stents. The SGH Tender is a group purchasing

program that serves the Ministries of Health in the six GCC members

states: United Arab Emirates, Kingdom of Bahrain, Kingdom of Saudi

Arabia, Sultanate of Oman, State of Qatar and State of Kuwait.

o Stentys received CE Marking for its Sirolimus-Eluting Stent (SES), in

the treatment of severe heart attacks. The French company can

market its SES in Europe immediately and, starting in 2015, in the

many other countries where the Company has commercial activity.

o Stentys signed a five year agreement with the company Micell

Technologies Inc. to distributute the MiStent coronary stent worldwide

(excluding the United States, Canada, China, South Korea and

Japan).

o Valneva signed two new research agreements in Japan in order to

develop human and veterinary vaccines.

o Valneva and UK company BliNK Therapeutics Ltd will create a new

private company specialized in the discovery of innovative monoclonal

antibodies.

o Valneva initiated a Phase II clinical trial of its VLA84 prophylactic

vaccine candidate against Clostridium difficile (C. difficile).

o Vexim has been chosen to be included in the new EnterNext© PEA-

PME 150 index.

o Vexim lauched a capital increase without preferential subscription

rights via a private placement for an amount of 5 million Euros.

o Vexim announced the approval by the FDA of the commercialization

in the United States of the MasterflowTM Injection System to treat

vertebral fractures where reducing and stabilizing the fracture is the

priority.



o Vexim ranked at the 4th place of the PME Finance / Morningstar

Futur40’s ranking. The Futur40 index gathers the 40 companies

publicly-listed on Euronext which has most increased their revenue

during the three last years. The revenue of the French life science

company has increased by 80.4% during this period.



2013

o Agrauxine is sold to Lesaffre Group. Agrauxine focuses its activity on

the development of bio-control products.

o Biomerieux completed the acquisition of Biofire Diagnostics for an

amount of $450 million (329 million Euros).

o EOS imaging announces the acquisition of OneFit Medical for an

amount of 4 million Euros.

o Eurofins strengthens its bioanalysis activity thanks to Merck KGAA.

o Eurofins SCIENTIFIC purchases IDMYK laboratory.

o Hybrigenics announces the acquisition by Hybrigenics Services, its

proteins interactions specialized branch, of the Dualsystems Biotech’s

double-hybrid screening platforms in yeast.

o Hybrigenics announces the acquisition of Imaxio’s genomics activities

in addition to a 1.3 million Euros fund raising resulting in a private

placement dedicated to Pradeyrol Development.

o Indicia Production purchases Biotechnologie Appliqué.

o Nicox sets up a trading network in Italy thanks to the acquisition of

Eupharmed.

o Transgene announces the acquisition of the immuno-monitoring

activities of the company Indicia Biotech by Platine Pharma Services,

one of its participations.

o Transgene announces its investment in the capital of ElsaLys Biotech.

The biotech company has invested in a first funding round worth 2.1

million Euros.

o Transgene is willing to sell to the South-Korean company Sillajen its

8.5% participation in Jennerex.



2012

o At the end of October 2012, Biosynex announced the acquisition of

the rapid diagnostics tests activity of the German company Sensogen.

o On November 06, 2012, Exonhit announced the acquisition of Ingen

Biosciences for an amount of 19 million Euros; the new born company

is known as Diaxonhit.

o On December 24, 2012, Eurofins announced the acquisition of Cerep.

o On March 2012, Eclat Pharmaceuticals has been acquired by Flamel

Technologies for an amount of $12 million (8.8 million Euros) .

o After Tekka’s bankruptcy, the company has been taken over by Menix

since September 2012.

o On December 21, 2011, Novagali Pharma was sold to the Japanese

company Santen Pharmaceutical for an amount of 102 million Euros.

o On June 27, 2012, Theradiag acquired Prestizia.

o On December 18, 2012, Vivalis announced the acquisition of Intercell

for an amount of 133 million Euros; the newborn company is known as

Valneva since June 2013.



Main venture capital actors in the French Life

Sciences Industry

1) Bpifrance

2) CM-CIC Capital Privé

3) Sofinnova Partners

4) Truffle Capital

5) Seventure Partners

6) Edmond de Rothschild Partner

7) Idinvest Partners

8) Omnes Capital

9) Auriga Partners

10) Midi Capital



Financial support from Bpifrance and the ANR

Bpifrance

Since July 12, 2013, Oseo, CDC Entreprises, FSI and FSI Régions have merged to give birth to Bpifrance. The new institution is willing to invest €1.7 billion in innovative small and mid-size companies until 2017.

2014

Vexim: €5 million, in January

Gensight Bilogics: €3 million, in March

Gamamabs Pharma: €0.6 million, in March

Diaxonhit: €1.7 million, in April

Carbios: €0.7 million, in December

Carmat: €5.2 million, in December

2013

Antabio: €0.74 million

CellProthera: €4.6 million, in July

Global Bioenergies: €740,000

Nanobiotix: €9 million, in July

2012

Eyevensys: €0.65 million, in January

Novasep: €30 million, in March

Valneva: €25 million, in December

Stentys: €15 million, in October

DBV Technologies: €15 million, in March

2011

Cellectis: €25 million, in September

DBV Technologies: €6 million, in November

Advicenne Pharma: €3 million, in May

2010

Adocia: €6 million, in January

Genticel: €3 million, in July

Poxel: €5 million, in September

Art: €3.3 million, in November

Supersonic Imagine: €4.75 million, in November

Cerenis: €20 million, in July



ANR

2012

9 calls for projects in the various health support

91 projects were funded for a total amount of €53.3 million

2010

14 projects funded for an amount of €9.6 million

2009


24 projects for an amount of €5.3 million

2008


28 projects for an amount of €6.7 million



Competitiveness Clusters

7 competitiveness clusters are directly attached to the biopharmaceutical sector in France. Additionally, an alliance between the Orpheme, Bio-Mediterranean and Holobiosuf clusters recently led to the formation of the Eurobiomed cluster.

List of the competitiveness clusters:

Alsace Biovalley, global-oriented cluster

Region: Alsace Project Leader: Alsace BioValley Primary focus areas: Genetic drugs, Pharmaceutical chemistry,

Imagery, Medical robots and Surgery. Visit the cluster website: http://www.alsace-biovalley.com

Atlantic Biotherapies Region: Pays de la Loire

Project Leader: association Atlantic Biothérapies20

Primary focus areas: Bio-diagnostics and biomedicine (discovery, vectorization, production and clinical evaluation of biomedicines) Visit the cluster website: http://www.atlantic-biotherapies.com/

Cancer Bio Santé

Regions : Midi-Pyrénées and Limousin Project Leader : Cancer Bio Santé Association Primary focus areas: Cancer (therapies, biomarkers, diagnostics,

imagery and medical devices) Visit the cluster website: http://www.cancerbiosante.fr/

Eurobiomed, Region: Languedoc Roussillon and Provence Alpes Côte d'Azur

Project Leader: competitiveness cluster ORPHEME and Holobiosud and Bioméditerranée clusters Primary focus areas: new pathologies and orphan diseases

Visit the cluster website: http://www.eurobiomed.org/

Lyon Biopôle, global cluster Region: Rhône-Alpes Project Leader: Association Lyon Biopôle

Primary focus areas: Infectious diseases, Virology, Immunology and Viralinduced cancers. Visit the cluster website: www.lyonbiopole.com

http://www.alsace-biovalley.com/

http://www.atlantic-biotherapies.com/

http://www.cancerbiosante.fr/

http://www.eurobiomed.org/

http://www.lyonbiopole.com/



Medicen (originally named MédiTech Santé Paris Région), global

cluster Region: Ile de France Project Leader: Association Méditech Santé Paris Région

Primary focus areas: Advanced technologies and new therapies for human health, Neuroscience, Oncology, Infectious diseases, Cellular and Molecular Medicine, Biomedical imagery and general drug

sciences. Visit the cluster website: http://www.medicen.org/

Nutrition Santé Longévité Region: Nord -Pas- de- Calais Project Leader: Nutrition Santé Longévité Cluster Association

Primary focus areas: Nutrition (nutrient delivery systems for metabolic disorders and aging) Visit the cluster website: http://www.pole-nsl.org

http://www.medicen.org/

http://www.pole-nsl.org/



3, 5 impasse Reille

75014 Paris Tel : 01 56 58 10 70

Facts and Figures 2014 December 2014

Documents

Transcript of Facts and Figures 2014 December 2014